{"protocolSection":{"identificationModule":{"nctId":"NCT01006993","orgStudyIdInfo":{"id":"CD-0258"},"organization":{"fullName":"CoAxia","class":"INDUSTRY"},"briefTitle":"Feasibility and Safety of NeuroFlo in Stroke Patients Receiving Tissue Plasminogen Activator","officialTitle":"Feasibility and Safety of NeuroFlo in Stroke Patients Receiving tPA","acronym":"FASTFlo tPA"},"statusModule":{"statusVerifiedDate":"2010-03","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2007-05"},"primaryCompletionDateStruct":{"date":"2009-07","type":"ACTUAL"},"completionDateStruct":{"date":"2010-01","type":"ACTUAL"},"studyFirstSubmitDate":"2009-11-02","studyFirstSubmitQcDate":"2009-11-02","studyFirstPostDateStruct":{"date":"2009-11-03","type":"ESTIMATED"},"lastUpdateSubmitDate":"2010-03-10","lastUpdatePostDateStruct":{"date":"2010-03-11","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"oldNameTitle":"Lori Austin","oldOrganization":"CoAxia, Inc."},"leadSponsor":{"name":"CoAxia","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"To assess the safety and feasibility of using the NeuroFlo catheter to treat acute ischemic stroke patients following administration of intravenous tPA."},"conditionsModule":{"conditions":["Ischemic Stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":22,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"NeuroFlo Treatment","type":"EXPERIMENTAL","interventionNames":["Device: NeuroFlo catheter"]}],"interventions":[{"type":"DEVICE","name":"NeuroFlo catheter","description":"NeuroFloâ„¢ catheter 45 minute treatment","armGroupLabels":["NeuroFlo Treatment"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"An assessment of serious adverse events occurring in ischemic stroke patients undergoing NeuroFlo treatment.","timeFrame":"Baseline to 30 days post-treatment"}],"secondaryOutcomes":[{"measure":"Potential patient benefit will be assessed through collection of neurological indices.","timeFrame":"Baseline through 90 days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Ischemic stroke\n* NIHSS between 5-22\n* Persistent clinical deficits following administration of rt-PA\n\nExclusion Criteria:\n\n* Planned thrombectomy\n* Aortic pathology\n* Severe heart disease\n* Other conditions the doctor will assess","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"FASTFlo Steering Committee","affiliation":"Various","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"University of Alberta","city":"Edmonton","state":"Alberta","zip":"T6G 2B7","country":"Canada","geoPoint":{"lat":53.55014,"lon":-113.46871}},{"facility":"University of Western Ontario","city":"London","state":"Ontario","zip":"N6A 5A5","country":"Canada","geoPoint":{"lat":42.98339,"lon":-81.23304}},{"facility":"Trillium Health Centre","city":"Mississauga","state":"Ontario","zip":"L5B 4A2","country":"Canada","geoPoint":{"lat":43.5789,"lon":-79.6583}},{"facility":"University of Erlangen","city":"Erlangen","zip":"91054","country":"Germany","geoPoint":{"lat":49.59099,"lon":11.00783}}]},"referencesModule":{"references":[{"pmid":"21350210","type":"DERIVED","citation":"Emery DJ, Schellinger PD, Selchen D, Douen AG, Chan R, Shuaib A, Butcher KS. Safety and feasibility of collateral blood flow augmentation after intravenous thrombolysis. Stroke. 2011 Apr;42(4):1135-7. doi: 10.1161/STROKEAHA.110.607846. Epub 2011 Feb 24."}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M13539","name":"Tissue Plasminogen Activator","relevance":"LOW"},{"id":"M13538","name":"Plasminogen","relevance":"LOW"}],"browseBranches":[{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}